Trabectedin

Drug Profile

Trabectedin

Alternative Names: Ecteinascidin; Ecteinascidin-743; ET-743; NSC-684766; Yondelis

Latest Information Update: 15 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Illinois
  • Developer European Organisation for Research and Treatment of Cancer; Johnson & Johnson; PharmaMar; Taiho Pharmaceutical
  • Class Antineoplastics; Dioxoles; Small molecules; Tetrahydroisoquinolines
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors; Macrophage inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer; Soft tissue sarcoma
  • Phase III Fallopian tube cancer; Peritoneal cancer
  • Phase II Liposarcoma; Meningioma; Mesothelioma
  • No development reported Breast cancer; Prostate cancer

Most Recent Events

  • 14 Jun 2017 Efficacy and adverse events data from a phase II trial in Mesothelioma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 02 Jun 2017 Updated efficacy and adverse events data from a phase III trial in Liposarcoma or leiomyosarcoma (Second-line therapy or greater) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 07 Apr 2017 Efficacy data from a clinical trial in Liposarcoma released by PharmaMar
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top